Slide 1: CTS Corporation 4th Quarter and Full-Year 2025 Earnings Call
CTS Corporation 4th Quarter and Full-Year 2025 Earnings Call February 10, 2026
Slide 2: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements Readers are cautioned that the statements contained in this document regarding expectations of our performance or other matters that may affect our business, results of operations, or financial condition are, or may be deemed to be, “forward-
Slide 3: Q4 and Full-Year 2025 – Strong Growth in Diversified Markets and Operational Execution
Solid growth from diversified end markets2 Revenue +9% for Q4 2025 Revenue +5% for full year 2025 59% of total revenue in Q4 2025 57% of total revenue for full year 2025 Transportation end market challenging Revenue flat for Q4 2025 Revenue (7)% for full year 2025 Lower sales of commercial vehicle p
Slide 4: End Markets Update: Medical and Aerospace & Defense
Medical $85 4 Aerospace & Defense ($ Millions) Revenue $83 ($ Millions) FY 2025 Sales up 21%; book to bill 1.07 Q4 2025 Sales up 41% vs. Q4 2024 Robust growth driven by therapeutic and minimally invasive applications Multiple Q4 wins across all regions in medical ultrasound, therapeutic applications
Slide 5: End Markets Update: Industrial and Transportation
End Markets Update Industrial 1 Refer to slide 2 for information on total booked business. 5 Transportation ($ Millions) FY 2025 Sales up 12%; book to bill 1.11 Q4 Sales up 16% year-over-year Continued recovery from cyclical lows across OEM and distribution customers Multiple Q4 wins across distribu
Slide 6: FY 2026 Guidance
$2.45 $2.30 Notes: 1 Adjusted Diluted EPS is a non-GAAP financial measure. Refer to the Appendix for reconciliations of non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. FY 2026 Guidance Revenue ($ Millions) Adjusted Dilu
Slide 7: 4th Quarter and Full-Year 2025 Financial Results
4th Quarter and Full-Year 2025 Financial Results
Slide 8: Q4 2025 Financial Summary
Notes: All comparisons vs. same period in prior year unless otherwise noted. 1 Adj. Diluted EPS, Adj. Gross Margin and Adj. EBITDA Margin are non-GAAP financial measures. Refer to the Appendix for reconciliations of non-GAAP financial measures to the most directly comparable financial measures calcu
Slide 9: Full-Year 2025 Financial Summary
Notes: All comparisons vs. same period in prior year unless otherwise noted. 1 Adj. Diluted EPS, Adj. Gross Margin and Adj. EBITDA Margin are non-GAAP financial measures. Refer to the Appendix for reconciliations of non-GAAP financial measures to the most directly comparable financial measures calcu
Slide 10: Strong Balance Sheet: Solid Foundation for Strategic M&A
Cash and Debt1 $62M Cash Returned to Shareholders FY 20253 $86M FY 2025 Free Cash Flow2 Strong Balance Sheet Solid Foundation for Strategic M&A $16M FY 2025 Capital Expenditures Borrowed Total Facility Operating Cash Flow Prioritizing strong cash flow generation ($ Millions) ($ Millions) Notes: 1 Ca
Slide 11: Q&A
Q&A cts
Slide 12: Appendix
Appendix cts
Slide 13: Non-GAAP Financial Measures
Non-GAAP Financial Measures From time to time, CTS may use non-GAAP financial measures in discussing CTS’ business. These measures are intended to supplement, not replace, CTS’ presentation of its financial results in accordance with U.S. GAAP. CTS believes that the non-GAAP financial measures prese
Slide 14: Regulation G Schedules: Adjusted Gross Margin
Regulation G Schedules ($ Millions, except percentages) Adjusted Gross Margin Three Months Ended December 31, Three Months Ended September 30, Twelve Months Ended December 31, 2025 2024 2025 2025 2024 2023 Gross margin $ 53.7 $ 46.9 $ 55.3 $ 208.0 $ 187.6 $ 190.9 Net sales $ 137.3 $ 126.5 $ 143.0 $
Slide 15: Regulation G Schedules: Adjusted Operating Earnings
Regulation G Schedules ($ Millions, except percentages) Adjusted Operating Earnings Three Months Ended December 31, Twelve Months Ended December 31, 2025 2024 2025 2024 2023 Operating earnings $ 22.7 $ 18.0 $ 82.6 $ 71.2 $ 75.1 Net sales $ 137.3 $ 126.5 $ 541.3 $ 514.8 $ 550.4 Operating earnings as
Slide 16: Regulation G Schedules: Adjusted EBITDA Margin
Regulation G Schedules ($ Millions, except percentages) Adjusted EBITDA Margin Three Months Ended December 31, Three Months Ended September 30, Twelve Months Ended December 31, 2025 2024 2025 2025 2024 2023 Net earnings (loss) $ 19.7 $ 11.6 $ 13.7 $ 65.3 $ 55.5 $ 60.5 Net sales $ 137.3 $ 126.5 $ 143
Slide 17: Regulation G Schedules: Adjusted Net Earnings and Adjusted Diluted EPS
Regulation G Schedules ($ Millions, except percentages and per share amounts) Adjusted Net Earnings and Adjusted Diluted Earnings Per Share Three Months Ended December 31, Three Months Ended September 30, 2025 2025 2024 2024 2025 2025 Per share Per share Net earnings (A) $ 19.7 $ 0.67 $ 11.6 $ 0.38
Slide 18: Regulation G Schedules: Adjusted Net Earnings and Adjusted Diluted EPS
Regulation G Schedules ($ Millions, except percentages and per share amounts) Adjusted Net Earnings and Adjusted Diluted Earnings Per Share NOTE: CTS believes that adjusted gross margin, adjusted operating earnings, adjusted EBITDA margin, adjusted net earnings and adjusted diluted earnings per shar
Slide 19: Reconciliation footnotes
Reflected in Selling, general and administrative and other income (expense), net. Reflected in Cost of goods sold. Reflected in Restructuring charges. Reflected in Other income (expense), net. Reflected in Income tax expense. For 2023, discrete tax items include adjusting for tax benefits resulting
Slide 20: Regulation G Schedules: Free Cash Flow and Controllable Working Capital
($ Millions, except percentages) Free Cash Flow ($ Millions, except percentages) Controllable Working Capital NOTE: CTS believes the controllable working capital ratio is a useful measure because it provides an objective measure of the efficiency with which CTS manages its short-term capital needs.